Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palovarotene in FOP (MOVE)
NCT03312634Phase 3Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Nov 2017
- Primary completion
- Jan 2020
- Modality
- Orthosteric Ligands
- Countries
- 11
01
Overview
A Phase 3 trial of palovarotene in fibrodysplasia ossificans progressiva (FOP), sponsored by Clementia Pharmaceuticals Inc.. Started Nov 2017; status: completed.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT03312634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312634.